ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SCLP Scancell Holdings Plc

14.25
-0.25 (-1.72%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Holdings Plc LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25 -1.72% 14.25 14.00 14.50 14.25 14.00 14.00 1,152,228 11:56:50
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 5.27M -11.94M -0.0129 -11.05 134.53M
Scancell Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 14.50p. Over the last year, Scancell shares have traded in a share price range of 7.65p to 18.125p.

Scancell currently has 927,819,977 shares in issue. The market capitalisation of Scancell is £134.53 million. Scancell has a price to earnings ratio (PE ratio) of -11.05.

Scancell Share Discussion Threads

Showing 67901 to 67923 of 68025 messages
Chat Pages: 2721  2720  2719  2718  2717  2716  2715  2714  2713  2712  2711  2710  Older
DateSubjectAuthorDiscuss
25/7/2024
07:28
Posts crossed there Plasybryn
marcusl2
25/7/2024
07:27
Correct but you still pay IHT.

CGT pn shares outside ISA is 20% for an additional or higher rate taxpayer. I envisage that this Marxist government will raise that to 40%.

Problem with IHT relief on AIM shares is that Inland Rev will not tell you if the company qualifies until death as I understand it.

Many Aim shares, whether held inside or outside an Isa, qualify for Business Relief (BR) which means they can be passed on to your heirs IHT-free.

Farms the King and businesses can avoid IHT altogether.

Again I can see Stalin Starmer changing that.

marcusl2
25/7/2024
07:22
Tax free in an ISA, except IHT but protected by Business Relief Tax if held over 2 years continuously. SIPP's are IHT free and can be handed on to beneficiaries. But taxable at marginal income tax rate when cash withdrawn. No CGT to pay. That is my understanding. No expert.
plasybryn
24/7/2024
23:16
no capital gains tax in ISA
inanaco
24/7/2024
22:42
Keytruda/vaccine
marcusl2
24/7/2024
22:36
But Scancell will be taken over so CGT is due then. IHT would be irrelevant.

Entrepreneurs’ Relief
You own at least 5% of the shares and voting rights.
You’re an employee or officeholder (director).
Your business has been trading for at least 24 months to qualify for ER / BADR relief.

Our only hope is shares in the acquiring company e.g. Roche shares if they buy SCLP. Unfortunately most deals are cash.

The new holding is treated as having been acquired at the same cost and at the same time as the original shares and CGT will only apply on a disposal of the new holding.

marcusl2
24/7/2024
21:53
sorted thanks Rats

ratcliffewriter

Posts: 10,881

Price: 14.50

Strong Buy

On t'other sideToday 20:32
Nana wondering if Scancell shares qualify for exemption from IHT if held for two years plus. Answer - yes, they do. I've had that info from my stockbroker, financial adviser and accountant, and even checked with the IHT helpline. But it is a two year absolute time - one year and 364 days, liability is there, two years- no liability.

inanaco
24/7/2024
21:52
Cleanerworld

Posts: 2,032

Price: 14.50

No Opinion

Maybe Merck know something better than personalised melanomaToday 21:26
Interesting. Maybe Merck know there is something much better:)

hxxps://www.biospace.com/deals/should-merck-buy-out-moderna-on-keytruda-cancer-vaccine-partnership


saw that myself so had a chat with the editor about scancell


Jef Akst

You

Thanks, @@@@. Appreciate the information. I’ll have a closer look!



Kind regards,

Jef

inanaco
24/7/2024
19:34
does Scancell fit the Bill ...............
inanaco
24/7/2024
19:34
Which AIM stocks are IHT exempt?

Most AIM stocks are exempt from inheritance tax (IHT) if they've been held for more than two years, and depending on individual circumstances it may be possible for AIM shareholders to qualify for the income tax and CGT reliefs when held via an Enterprise Investment Scheme, or through CGT Entrepreneurs Relief.

To qualify, a company must be a trading company carrying out the majority of its business in the UK. Businesses trading in land or securities, or receiving a substantial amount of income from letting property or land, are excluded.

inanaco
24/7/2024
19:29
does any one know about AIM BPR-qualifying companies ?

something i just read in the telegraph

Shares listed on the Aim market – a submarket of the London Stock Exchange – are eligible for 100pc inheritance tax relief once an investor has held them for two years, and provided the shares also qualify for business relief.

inanaco
24/7/2024
17:05
but i suppose somebody like Ruck who has proven his ability in Maths by successfully adjusting his data set criteria to get the right result knows all about "Fraud"

he has cheated his bosses for years convincing them he understood probabilities

what a charade that was ...

But if you think a digital currency is something special think again .... and actually needs understanding think again ...

all you need is to be stupid .. pressing buy and sell on fantasy waves

but if a fraud is discovered while u are holding ........... expect a price crash

AI Overview
Learn more

Cryptocurrency is a digital currency that allows people to make electronic payments to each other online. It's also known as virtual currency or digital money. Cryptocurrencies are secured by cryptography, making them difficult to counterfeit or double-spend. They're not backed by a central bank or government, and their value is based on what people are willing to pay for them in the market

inanaco
24/7/2024
16:58
Dont need to understand it .....

I am not laundering money across borders

inanaco
24/7/2024
16:50
Inan"crypto its a fantasy currency with no intrinsic value"lol. The only reason you think that is because you don't understand it.Similar to all the people who don't understand Scancell who you lambast. Ironic really!
ruckrover
24/7/2024
16:45
This could all happen by 2026

personally i think Bristol Myers will step in to Partner Scancell on Immunobdy and Moditope

if the double CPi works for Modi1 .... they will be extremely interested

the buy in price would be billions

because it would be a step change in the number of trials we could run

Labour and the conservatives came after and coming after wealth .... its the only tax they can screw you on

from cutting interest payments from rents reducing capital gains tax and share dividend allowance you really need to understand Tax if you follow what i am posting because we are getting close to trial we can predict

all the numbers are transparent

but it all starts with

"the number you hold"

inanaco
24/7/2024
16:29
best post on the LSE ................... that actually gets close to the mark


Dalester

Posts: 467

Price: 14.50

No Opinion

RE: Never at £500mToday 16:25
The potential annual revenue for scib / melanoma is $1.5Bn. Current deals are running at over 5 times annual revenue and with the potential to be under patent for 15 years, no one is going to sell scib alone much less the whole platform for under £5bn and that would probably be cheap if it is as effective as now seems possible.. And melanoma is the fastest growing cancer on the planet in terms of incidents needing treatment so the revenue will rise year on year... Add to that the fact that there are 100s of billions of Dollars looking for new products to protect current levels of profits and we are perfectly positioned to cash in. Redmile know what the score is , they have put someone on the Board to make sure we maximise their investment.

inanaco
24/7/2024
16:09
may 2024

This approval marks another milestone for Scancell, and the promising "efficacy", safety and tolerability study "generated" from earlier cohorts underscore our belief that our Modi-1 cancer vaccine has the potential to deliver a step change in the treatment of renal and other hard-to-treat cancers."

so much news

just remember that scancell can announce 27 responders any time on SCIB1

these results coming Q4 and Q1 2025 are still interim

with SCIB1 ... it could include PFS ...... standard of care is 11.5 months

inanaco
24/7/2024
16:08
Keep collecting the loose change inane...lol
Think crypto...tens of 1000's of % !!
Analysts ? Nothing to do with stock prices WHATSOEVER.

2tyke
24/7/2024
14:57
Madeleine Armstrong
@ByMadeleineA
·
SCIB1 data now due in Q4 2024 (from Q3), and iSCIB1+ in Q1 2025 (from Q4 2024). Here's my recent interview with Scancell, via
@ApexOnco

marcusl2
24/7/2024
14:14
The thing is, it is the management itself that should provide the realistic perspective. It is a tough one, because if one is say a carpenter (or an accountant, looking at you Bermuda, or whatever that is not drug development related) that wants to invest part of their income in an ISA, can you really blame them for listening to an established scientist that also happens to be a (non established) CEO vs an anonymous person on a board (regardless of what they might say they are)?

And from the perspective of an analyst, and I've met a few (anonymous board, I know, but if anyone can vomit what they want so can I), what are they supposed to project when basic "facts" used to (maximum hopium here) change often in the same day?

sci102
24/7/2024
13:47
'completely the wrong premise' about stock prices. says the Guru

glad i have ..............

hence i hold 1.566m at very cheap prices ....

all you do is Yap yap yap

inanaco
24/7/2024
13:43
this is why i keep saying the "probability" calculations don't change from this trial to the next

because you are not changing the treatment regime ....

you have potentially an ORR at 85% why would you change it .............

inanaco
24/7/2024
13:40
Not quite ...

adaptive means you can change the size of the trial etc based on data seen in the phase 2 adaptive, and you have a third party review of that data to move to a phase 3 and potentially an interim approval

it does not mean you change all the protocols of treatment as that would not allow you to proceed to a phase 3 without a second review of those changes ...,.

so any changes in the way you treat is done NOW in the current trial

inanaco
Chat Pages: 2721  2720  2719  2718  2717  2716  2715  2714  2713  2712  2711  2710  Older